Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Eosinophilia Clear all
Completed Phase 2 Interventional Results available

GB001 in Adult Subjects With Moderate to Severe Asthma

NCT03683576
View directory record Official record
Conditions
Asthma
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Jun 10, 2026, 2:12 PM EDT
Completed No phase listed Observational

Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)

NCT01929824
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Nitric Oxide testing
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Jun 10, 2026, 2:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT06598462
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
Biological · Other
Lead sponsor
Uniquity One (UNI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
38
States / cities
Dothan, Alabama • Glendale, Arizona • Peoria, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

NCT01290887
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jun 10, 2026, 2:12 PM EDT
Recruiting Phase 3 Interventional

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

NCT06596252
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Budesonide
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Pilot Study of Esocheck in Eosinophilic Esophagitis

NCT04311970
View directory record Official record
Conditions
Eosinophilic Esophagitis, Diagnoses Disease
Interventions
EsoCheck
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Jun 10, 2026, 2:12 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

NCT01921686
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
Interventions
Sample collection and Questionnaire
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional Results available

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

NCT03245840
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Budesonide oral suspension
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional

Phase III Long-Term Extension Study With Dexpramipexole

NCT06388889
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Dexpramipexole Dihydrochloride
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Bakersfield, California • Northridge, California • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Active, not recruiting Phase 4 Interventional

Dupilumab for Eosinophilic Esophagitis With Severe Strictures

NCT06352073
View directory record Official record
Conditions
Eosinophilic Esophagitis, EoE
Interventions
Dupilumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

NCT03011372
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
9
States / cities
Phoenix, Arizona • Duarte, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis

NCT07234825
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Partial enteral nutrition (PEN) with dairy elimination, Dairy elimination alone
Other
Lead sponsor
Kate Farms Inc
Industry
Eligibility
1 Year to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Active, not recruiting No phase listed Observational

Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children

NCT05309590
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dose
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 21 Years
Enrollment
50 participants
Timeline
2014 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

NCT00132015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition, Precancerous Condition
Interventions
tanespimycin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jun 10, 2026, 2:12 PM EDT
Active, not recruiting No phase listed Observational

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

NCT01988285
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Specimen Collection, Questionnaires
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853
View directory record Official record
Conditions
Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Imaging of the Esophagus Using a SECM Capsule

NCT03546660
View directory record Official record
Conditions
Eosinophilic Esophagitis, Barrett Esophagus
Interventions
SECM capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of Flovent in Patients With Eosinophilic Esophagitis

NCT00426283
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Flovent, Placebo
Drug · Other
Lead sponsor
Marc Rothenberg, MD
Other
Eligibility
3 Years to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Montelukast in the Treatment of Duodenal Eosinophilia

NCT00148603
View directory record Official record
Conditions
Eosinophilic Gastroenteritis, Dyspepsia
Interventions
montelukast
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

A Study of Baked Milk Tolerance to Treat Eosinophilic Esophagtis

NCT05606705
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Baked Milk
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Topical Steroid Treatment for Eosinophilic Esophagitis

NCT00275561
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Fluticasone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Jun 10, 2026, 2:12 PM EDT